Financhill
Sell
49

PCVX Quote, Financials, Valuation and Earnings

Last price:
$36.40
Seasonality move :
23.78%
Day range:
$35.58 - $36.56
52-week range:
$27.66 - $121.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.47x
Volume:
1.2M
Avg. volume:
1.5M
1-year change:
-55.84%
Market cap:
$4.7B
Revenue:
--
EPS (TTM):
-$3.99

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PCVX
Vaxcyte
-- -$1.16 -- -5.64% $125.75
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
CVM
CEL-SCI
-- -- -- -- $8.00
IGC
IGC Pharma
$326K -$0.03 3.39% -50% $3.88
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$13.5M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PCVX
Vaxcyte
$36.38 $125.75 $4.7B -- $0.00 0% --
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
CVM
CEL-SCI
$3.63 $8.00 $11M -- $0.00 0% --
IGC
IGC Pharma
$0.37 $3.88 $31.4M -- $0.00 0% 22.56x
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$1.42 $14.00 $113M 35.50x $0.00 0% 1.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PCVX
Vaxcyte
-- 2.837 -- --
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
CVM
CEL-SCI
-- -0.752 -- --
IGC
IGC Pharma
2.1% 0.356 0.51% 0.21x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- -1.225 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PCVX
Vaxcyte
-- -$180.8M -- -- -- -$193M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Vaxcyte vs. Competitors

  • Which has Higher Returns PCVX or AIM?

    AIM ImmunoTech has a net margin of -- compared to Vaxcyte's net margin of -10571.43%. Vaxcyte's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$1.04 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About PCVX or AIM?

    Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 245.66%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Vaxcyte, analysts believe AIM ImmunoTech is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    9 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is PCVX or AIM More Risky?

    Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock PCVX or AIM?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or AIM?

    Vaxcyte quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Vaxcyte's net income of -$140.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$140.7M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns PCVX or CVM?

    CEL-SCI has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$1.04 --
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About PCVX or CVM?

    Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 245.66%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 6512.23%. Given that CEL-SCI has higher upside potential than Vaxcyte, analysts believe CEL-SCI is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    9 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is PCVX or CVM More Risky?

    Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

  • Which is a Better Dividend Stock PCVX or CVM?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or CVM?

    Vaxcyte quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Vaxcyte's net income of -$140.7M is lower than CEL-SCI's net income of -$6.6M. Notably, Vaxcyte's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$140.7M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns PCVX or IGC?

    IGC Pharma has a net margin of -- compared to Vaxcyte's net margin of -711.67%. Vaxcyte's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$1.04 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About PCVX or IGC?

    Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 245.66%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 934.16%. Given that IGC Pharma has higher upside potential than Vaxcyte, analysts believe IGC Pharma is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    9 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is PCVX or IGC More Risky?

    Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

  • Which is a Better Dividend Stock PCVX or IGC?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or IGC?

    Vaxcyte quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Vaxcyte's net income of -$140.7M is lower than IGC Pharma's net income of -$1.8M. Notably, Vaxcyte's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 22.56x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$140.7M
    IGC
    IGC Pharma
    22.56x -- $257K -$1.8M
  • Which has Higher Returns PCVX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Vaxcyte's net margin of -49.65%. Vaxcyte's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$1.04 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About PCVX or NBY?

    Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 245.66%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 23.19%. Given that Vaxcyte has higher upside potential than NovaBay Pharmaceuticals, analysts believe Vaxcyte is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    9 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is PCVX or NBY More Risky?

    Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock PCVX or NBY?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or NBY?

    Vaxcyte quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vaxcyte's net income of -$140.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$140.7M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns PCVX or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to Vaxcyte's net margin of -35.79%. Vaxcyte's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$1.04 --
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About PCVX or PLX?

    Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 245.66%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 885.92%. Given that Protalix BioTherapeutics has higher upside potential than Vaxcyte, analysts believe Protalix BioTherapeutics is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    9 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is PCVX or PLX More Risky?

    Vaxcyte has a beta of 1.185, which suggesting that the stock is 18.527% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

  • Which is a Better Dividend Stock PCVX or PLX?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or PLX?

    Vaxcyte quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Vaxcyte's net income of -$140.7M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Vaxcyte's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 1.99x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$140.7M
    PLX
    Protalix BioTherapeutics
    1.99x 35.50x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
55
INKT alert for Jul 15

MiNK Therapeutics [INKT] is down 36.03% over the past day.

Sell
48
NEGG alert for Jul 15

Newegg Commerce [NEGG] is down 26.42% over the past day.

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is up 19.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock